Processa Pharmaceuticals, Inc.
PCSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533743
In the last 90 days, Processa Pharmaceuticals, Inc. insiders filed 5 open-market purchases and 0 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $498.3K in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Processa Pharmaceuticals, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- +1 vs. Q4 2025
- Shares held
- 177.7K
- +86.1K (+94.0%) vs. Q4 2025
- Total value
- $448.5K
- +$185.4K (+70.5%) vs. Q4 2025
- New holders
- 4
- 2 more added
- Sold out
- 3
- 2 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PCSA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $498.3K |
| Q1 2026 | 10 | $448.5K |
| Q4 2025 | 10 | $331.0K |
| Q3 2025 | 14 | $341.9K |
| Q2 2025 | 13 | $75.9K |
| Q1 2025 | 9 | $63.2K |
| Q4 2024 | 8 | $87.5K |
| Q3 2024 | 8 | $66.5K |
| Q2 2024 | 9 | $101.0K |
| Q1 2024 | 11 | $251.5K |
| Q4 2023 | 18 | $376.5K |
| Q3 2023 | 20 | $349.8K |
| Q2 2023 | 19 | $691.4K |
| Q1 2023 | 22 | $852.6K |
| Q4 2022 | 18 | $1.28M |
| Q3 2022 | 18 | $2.58M |
| Q2 2022 | 18 | $3.24M |
| Q1 2022 | 18 | $3.22M |
| Q4 2021 | 19 | $6.47M |
| Q3 2021 | 18 | $12.2M |
| Q2 2021 | 18 | $11.2M |
| Q1 2021 | 17 | $12.3M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Processa Pharmaceuticals, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 6 | $15 | 0.00% | 00.0% | Unchanged |
| Jones Financial Companies LLLP | 7 | $17 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 14 | $35 | 0.00% | +14 | New |
| Tower Research Capital LLC (TRC) | 918 | $2.32K | 0.00% | −472−34.0% | Reduced |
| UBS Group AG | 2,531 | $6.39K | 0.00% | −10,109−80.0% | Reduced |
| Vanguard Fiduciary Trust Co | 10,857 | $27.4K | 0.00% | +10,857 | New |
| Vanguard Capital Management LLC | 12,729 | $32.1K | 0.00% | +12,729 | New |
| Geode Capital Management, LLC | 24,908 | $62.8K | 0.00% | +9,585+62.6% | Added |
| Stonepine Capital Management, LLC | 55,000 | $138.9K | 0.12% | +42,677+346.3% | Added |
| Connective Capital Management, LLC | 70,736 | $178.6K | 0.15% | +70,736 | New |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −30,190−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −19,691−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |